Phase I trial of MK-0752 in children with refractory CNS malignancies: A pediatric brain tumor consortium study

Journal of Clinical Oncology

Volumn 29, Issue 26, 2011, Pages 3529-3534

  Fouladi, Maryam ^a   Stewart, Clinton F ^b   Olson, James ^c   Wagner, Lars M ^a   Onar Thomas, Arzu ^b   Kocak, Mehmet ^b   Packer, Roger J ^d   Goldman, Stewart ^e   Gururangan, Sridharan ^f   Gajjar, Amar ^b   Demuth, Tim ^g   Kun, Larry E ^b   Boyett, James M ^b   Gilbertson, Richard J ^b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b ST JUDE CHILDREN S RESEARCH HOSPITAL   (United States)

^c SEATTLE CHILDREN S HOSPITAL   (United States)

^d CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

^e CHILDREN'S MEMORIAL HOSPITAL   (United States)

^f DUKE UNIVERSITY MEDICAL CENTER   (United States)

^g MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MK 0752; NOTCH RECEPTOR; TRANSCRIPTION FACTOR HES 1;

ANOREXIA; AREA UNDER THE CURVE; ARTICLE; BLURRED VISION; BRAIN TUMOR; BRAINSTEM GLIOMA; CANCER GROWTH; CENTRAL NERVOUS SYSTEM TUMOR; CHILD; CHILDHOOD CANCER; CHOROID PLEXUS CARCINOMA; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; COUGHING; DIARRHEA; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG DOSE ESCALATION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG TOLERABILITY; EPENDYMOMA; FATIGUE; FEMALE; GLIOBLASTOMA; HUMAN; HYPERBILIRUBINEMIA; HYPERMAGNESEMIA; HYPOALBUMINEMIA; HYPOKALEMIA; HYPOMAGNESEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; LYMPHOCYTOPENIA; MALE; MAXIMUM TOLERATED DOSE; MEDULLOBLASTOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; NEUROECTODERM TUMOR; NEUTROPENIA; PAIN; PERIPHERAL BLOOD MONONUCLEAR CELL; PHARMACOKINETICS; PRIORITY JOURNAL; PROTEIN EXPRESSION; PRURITUS; RASH; RHABDOID TUMOR; SCHOOL CHILD; SIDE EFFECT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT RESPONSE; VOMITING; WEIGHT REDUCTION;

ADOLESCENT; AMYLOID PRECURSOR PROTEIN SECRETASES; ANTINEOPLASTIC AGENTS; BASIC HELIX-LOOP-HELIX TRANSCRIPTION FACTORS; CENTRAL NERVOUS SYSTEM NEOPLASMS; CHILD; CHILD, PRESCHOOL; DRUG TOXICITY; FEMALE; HOMEODOMAIN PROTEINS; HUMANS; MALE; MAXIMUM TOLERATED DOSE; PROPIONIC ACIDS; RECEPTOR, NOTCH1; RECURRENCE; REPRESSOR PROTEINS; SULFONES;

EID: 80053040376     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2011.35.7806     Document Type: Article

References (44)

1. Radtke F, Raj K: The role of Notch in tumorigenesis: Oncogene or tumour suppressor? Nat Rev Cancer 3:756-767, 2003 (Pubitemid 37328814)
2. Takebe N, Harris PJ, Warren RQ, et al: Targeting cancer stem cells by inhibiting Wnt, Notch, and Hedgehog pathways. Nat Rev Clin Oncol 8:97-106, 2011
3. Wolfe MS: Secretase targets for Alzheimer's disease: Identification and therapeutic potential. J Med Chem 44:2039-2060, 2001
4. Adelsberger H, Quasthoff S, Grosskreutz J, et al: The chemotherapeutic oxaliplatin alters voltagegated Na(+) channel kinetics on rat sensory neurons. Eur J Pharmacol 406:25-32, 2000
5. Yin L, Velazquez OC, Liu ZJ: Notch signaling: Emerging molecular targets for cancer therapy. Biochem Pharmacol 80:690-701, 2010
6. Kopan R, Ilagan MX: Gamma-secretase: Proteasome of the membrane? Nat Rev Mol Cell Biol 5:499-504, 2004
7. Cho HS, Mason K, Ramyar KX, et al: Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab. Nature 421:756-760, 2003 (Pubitemid 36227628)
8. Harper JA, Yuan JS, Tan JB, et al: Notch signaling in development and disease. Clin Genet 64:461-472, 2003 (Pubitemid 37493116)
9. Baker NE: Notch signaling in the nervous system: Pieces still missing from the puzzle. Bioessays 22:264-273, 2000
10. Zhao WL: Targeted therapy in T-cell malignancies: Dysregulation of the cellular signaling pathways. Leukemia 24:13-21, 2010
11. Harrison H, Farnie G, Brennan KR, et al: Breast cancer stem cells: Something out of notching? Cancer Res 70:8973-8976, 2010
12. Weijzen S, Rizzo P, Braid M, et al: Activation of Notch-1 signaling maintains the neoplastic phenotype in human Ras-transformed cells. Nat Med 8:979-986, 2002 (Pubitemid 35033702)
13. Brennan K, Brown AM: Is there a role for Notch signalling in human breast cancer? Breast Cancer Res 5:69-75, 2003 (Pubitemid 36348099)
14. Sonoshita M, Aoki M, Fuwa H, et al: Suppression of colon cancer metastasis by Aes through inhibition of Notch signaling. Cancer Cell 19:125-137, 2011
15. Lasky JL, Wu H: Notch signaling, brain development, and human disease. Pediatr Res 57:104R-109R, 2005 (Pubitemid 40593254)
16. Maliekal TT, Bajaj J, Giri V, et al: The role of Notch signaling in human cervical cancer: Implications for solid tumors. Oncogene 27:5110-5114, 2008
17. Tonon G, Modi S, Wu L, et al: t(11;19)(q21; p13) translocation in mucoepidermoid carcinoma creates a novel fusion product that disrupts a Notch signaling pathway. Nat Genet 33:208-213, 2003 (Pubitemid 36177076)
18. Pierfelice TJ, Schreck KC, Eberhart CG, et al: Notch, neural stem cells, and brain tumors. Cold Spring Harb Symp Quant Biol 73:367-375, 2008
19. Gaiano N: Strange bedfellows: Reelin and Notch signaling interact to regulate cell migration in the developing neocortex. Neuron 60:189-191, 2008
20. Zhou ZD, Kumari U, Xiao ZC, et al: Notch as a molecular switch in neural stem cells. IUBMB Life 62:618-623, 2010
21. Singh SK, Hawkins C, Clarke ID, et al: Identification of human brain tumour initiating cells. Nature 432:396-401, 2004 (Pubitemid 39551674)
22. Fan X, Eberhart CG: Medulloblastoma stem cells. J Clin Oncol 26:2821-2827, 2008
23. Taylor MD, Poppleton H, Fuller C, et al: Radial glia cells are candidate stem cells of ependymoma. Cancer Cell 8:323-335, 2005 (Pubitemid 41443417)
24. Hallahan AR, Pritchard JI, Hansen S, et al: The SmoA1 mouse model reveals that notch signaling is critical for the growth and survival of sonic hedgehog-induced medulloblastomas. Cancer Res 64:7794-7800, 2004 (Pubitemid 39446912)
25. Ignatova TN, Kukekov VG, Laywell ED, et al: Human cortical glial tumors contain neural stem-like cells expressing astroglial and neuronal markers in vitro. Glia 39:193-206, 2002
26. LoRusso P, Demuth T, Heath E, et al: Phase I Study of the gamma secretase inhibitor MK-0752 in patients with metastatic breast and other advanced solid tumors. 100th Annual Meeting of the American Association for Cancer Research, Denver, CO, April 18-22, 2009 (abstr 3605)
27. Efferson CL, Winkelmann CT, Ware C, et al: Downregulation of Notch pathway by a gamma-secretase inhibitor attenuates AKT/mammalian target of rapamycin signaling and glucose uptake in an ERBB2 transgenic breast cancer model. Cancer Res 70:2476-2484, 2010
28. Onar A, Kocak M, Boyett JM: Continual reassessment method vs. traditional empirically based design: Modifications motivated by Phase I trials in pediatric oncology by the Pediatric Brain Tumor Consortium. J Biopharm Stat 19:437-455, 2009
29. Kieran MW, Packer RJ, Onar A, et al: Phase I and pharmacokinetic study of the oral farnesyltransferase inhibitor lonafarnib administered twice daily to pediatric patients with advanced central nervous system tumors using a modified continuous reassessment method: A Pediatric Brain Tumor Consortium Study. J Clin Oncol 25:3137-3143, 2007 (Pubitemid 47218063)
30. Bai F, Tagen M, Colotta C, et al: Determination of the gamma-secretase inhibitor MK-0752 in human plasma by online extraction and electrospray tandem mass spectrometry (HTLC-ESI-MS/MS). J Chromatogr B Analyt Technol Biomed Life Sci 878:2348-2352, 2010
31. Gajjar A, Hernan R, Kocak M, et al: Clinical, histopathologic, and molecular markers of prognosis: Toward a new disease risk stratification system for medulloblastoma. J Clin Oncol 22:984-993, 2004 (Pubitemid 41095029)
32. Gilbertson RJ, Bentley L, Hernan R, et al: ERBB receptor signaling promotes ependymoma cell proliferation and represents a potential novel therapeutic target for this disease. Clin Cancer Res 8:3054-3064, 2002 (Pubitemid 35155014)
33. Deangelo DJ, Stone RM, Silverman LB, et al: A phase I clinical trial of the Notch inhibitor MK-0752 in patients with T-cell acute lymphoblastic leukemia/lymphoma (T-ALL) and other leukemias. J Clin Oncol 24:357s, 2006 (suppl; abstr 6585)
34. Krop IE, Kosh M, Fearen I, et al: Phase I pharmacokinetic (PK), and pharmacodynamic (PD) trial of the novel oral Notch inhibitor MK-0752 in patients (pts) with advanced breast cancer (BC) and other solid tumors. J Clin Oncol 24:573s, 2006 (suppl; abstr 10574)
35. Real PJ, Tosello V, Palomero T, et al: Gamma-secretase inhibitors reverse glucocorticoid resistance in T cell acute lymphoblastic leukemia. Nat Med 15:50-58, 2009
36. Daw NC, Furman WL, Stewart CF, et al: Phase I and pharmacokinetic study of gefitinib in children with refractory solid tumors: A Children's Oncology Group Study. J Clin Oncol 23:6172-6180, 2005
37. Panetta JC, Kirstein MN, Gajjar A, et al: Population pharmacokinetics of temozolomide and metabolites in infants and children with primary central nervous system tumors. Cancer Chemother Pharmacol 52:435-441, 2003 (Pubitemid 37491631)
38. Tubergen DG, Stewart CF, Pratt CB, et al: Phase I trial and pharmacokinetic (PK) and pharmacodynamics (PD) study of topotecan using a five-day course in children with refractory solid tumors: A Pediatric Oncology Group study. J Pediatr Hematol Oncol 18:352-361, 1996 (Pubitemid 26359251)
39. Bill BR, Balciunas D, McCarra JA, et al: Development and Notch signaling requirements of the zebrafish choroid plexus. PLoS One 3:e3114, 2008
40. Garcia-Lecea M, Kondrychyn I, Fong SH, et al: In vivo analysis of choroid plexus morphogenesis in zebrafish. PLoS One 3:e3090, 2008
41. Dang L, Fan X, Chaudhry A, et al: Notch3 signaling initiates choroid plexus tumor formation. Oncogene 25:487-491, 2006 (Pubitemid 43117634)
42. Pancewicz J, Taylor JM, Datta A, et al: Notch signaling contributes to proliferation and tumor formation of human T-cell leukemia virus type 1-associated adult T-cell leukemia. Proc Natl Acad Sci U S A 107:16619-16624, 2010
43. Tammam J, Ware C, Efferson C, et al: Down-regulation of the Notch pathway mediated by a gamma-secretase inhibitor induces anti-tumour effects in mouse models of T-cell leukaemia. Br J Pharmacol 158:1183-1195, 2009
44. Rao SS, O'Neil J, Liberator CD, et al: Inhibition of NOTCH signaling by gamma secretase inhibitor engages the RB pathway and elicits cell cycle exit in T-cell acute lymphoblastic leukemia cells. Cancer Res 69:3060-3068, 2009